Who owns BridgeBio Oncology Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of BBOT from SEC Form 13F filings across 65 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 65 institutions disclosed 59.1M shares of BridgeBio Oncology Therapeutics, Inc. worth $450.6M — about 73.9% of shares outstanding; the largest disclosed holder is Cormorant Asset Management, LP. Source: SEC Form 13F filings, parsed by EvidInvest.
65
13F holders
$450.6M
value, 2026 filers
73.9%
of shares outstanding (59.1M sh)
16
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of BBOT's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Cormorant Asset Management, LP | 17.9M | $136.2M | 7.0% | 22.3% | 0.0% |
| 2 | DEERFIELD MANAGEMENT COMPANY, L.P. | 4.9M | $37.2M | 0.4% | 6.1% | 0.0% |
| 3 | Omega Fund Management, LLC | 3.3M | $25.1M | 13.5% | 4.1% | 0.0% |
| 4 | Alphabet Inc. | 2.8M | $21.5M | 0.0% | 3.5% | 0.0% |
| 5 | EcoR1 Capital, LLC | 2.8M | $21.5M | 1.0% | 3.5% | 0.0% |
| 6 | WELLINGTON MANAGEMENT GROUP LLP | 2.8M | $21.3M | 0.0% | 3.5% | -1.0% |
| 7 | ENAVATE SCIENCES GP, LLC | 2.6M | $20.0M | 5.8% | 3.3% | 0.0% |
| 8 | CITADEL ADVISORS LLC | 2.6M | $19.9M | 0.0% | 3.3% | +3.5% |
| 9 | NOVO HOLDINGS A/S | 2.3M | $17.1M | 1.0% | 2.8% | +2.9% |
| 10 | BlackRock, Inc. | 2.2M | $16.4M | 0.0% | 2.7% | +3.1% |
| 11 | VANGUARD CAPITAL MANAGEMENT LLC | 2.0M | $15.3M | 0.0% | 2.5% | +272.5% |
| 12 | Laurion Capital Management LP | 2.0M | $15.3M | 0.4% | 2.5% | +4.2% |
| 13 | ARMISTICE CAPITAL, LLC | 1.8M | $13.4M | 0.2% | 2.2% | +32.8% |
| 14 | STATE STREET CORP | 1.0M | $7.9M | 0.0% | 1.3% | +358.1% |
| 15 | Aisling Capital Management LP | 1.0M | $7.8M | 1.6% | 1.3% | 0.0% |
| 16 | Opaleye Management Inc. | 700,000 | $5.3M | 0.5% | 0.9% | +1213.8% |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 622,351 | $4.7M | 0.0% | 0.8% | +7.4% |
| 18 | Granahan Investment Management, LLC | 558,526 | $4.3M | 0.2% | 0.7% | +141.7% |
| 19 | SPHERA FUNDS MANAGEMENT LTD.NEW | 460,985 | $3.5M | 0.5% | 0.6% | new |
| 20 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 400,000 | $3.0M | 0.0% | 0.5% | 0.0% |
| 21 | ROYCE & ASSOCIATES LP | 384,941 | $2.9M | 0.0% | 0.5% | -39.5% |
| 22 | Catalio Capital Management, LPNEW | 318,407 | $2.4M | 0.5% | 0.4% | new |
| 23 | PRICE T ROWE ASSOCIATES INC /MD/ | 300,000 | $2.3M | 0.0% | 0.4% | -31.5% |
| 24 | VANGUARD FIDUCIARY TRUST CO | 291,522 | $2.2M | 0.0% | 0.4% | +14.6% |
| 25 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 286,518 | $2.2M | 0.0% | 0.4% | -1.5% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.